Demonstrates in vivo tumor suppression of CT-26 mouse colorectal cancer by adenovirus-expressed shRNA targeting TMSB4X. Adenoviral shRNA delivery specifically silenced TB4 expression in tumors and significantly reduced CT-26 tumor growth in vivo—the first in vivo gene silencing proof-of-concept for TB4 as a CRC therapeutic target. Translates the in vitro TB4 silencing data to an animal model, establishing adenoviral shRNA as a gene therapy tool for TB4 inhibition in CRC and providing a platform for evaluating TB4 knockdown in colorectal cancer therapy.
Chao, T-C; Chan, L-C; Ju, S-Y; Tang, M-C; Liu, C-Y; Chen, P-M; Tzeng, C-H; Su, Y